SALT LAKE CITY, Aug. 7, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular diagnostics company with a
unique, patented platform for the development of diagnostic tests,
announced today that Australia has
been added to the list of countries that have authorized the Logix
Smart™ COVID-19 for use in detecting SARS-CoV-2, the virus that
Australia joins the United States, India, Mexico, the European Community and others as a
region where the Company's test can be sold and used as a
coronavirus in vitro diagnostic (IVD). The Australian
Government Register of Therapeutic Goods Certificate was recently
issued to the Company's distributor in Australia, approving the distributor to supply
the Class 3 IVD to the Australian market.
Dwight Egan, CEO of
Co-Diagnostics, commented, "Co-Diagnostics recognizes the
importance of accurate, high-throughput testing in combating surges
of coronavirus infections, and we are gratified that our test is
being used to help people in so many countries to safely navigate
this ongoing pandemic, now also including Australia."
The news follows recent reports of a soaring coronavirus
outbreak in Melbourne, prompting
the state of Victoria to declare a
"state of disaster" and to strengthen lockdown measures.
The CE-marked and FDA EUA Co-Diagnostics Logix Smart COVID-19
test is currently available to all clinical laboratories certified
under Clinical Laboratory Improvement Amendments (CLIA), and is
authorized to be used for the diagnosis of SARS-CoV-2, the virus
that causes COVID-19, in the US and many other countries.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and
conditions. Forward-looking statements in this release include
statements regarding the (i) use of funding proceeds, (ii)
expansion of product distribution, (iii) acceleration of
initiatives in liquid biopsy and SNP detection, (iv) use of the
Company's liquid biopsy tests by laboratories, (v) capital
resources and runway needed to advance the Company's products and
markets, (vi) increased sales in the near-term, (vii) flexibility
in managing the Company's balance sheet, (viii) anticipation of
business expansion, and (ix) benefits in research and worldwide
accessibility of the CoPrimer technology and its cost-saving and
scientific advantages. Forward-looking statements are subject to
inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
Head of Investor
View original content to download